Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Tumor-Agnostic 2Thoracic 2Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Neoplasms 9Carcinoma 4Neoplasm Metastasis 2

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Axitinib × Tumor-Agnostic × Clear all
NCT04693468 2026-03-13

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M.D. Anderson Cancer Center

Phase 1 Recruiting
111 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04698213 2021-01-06

TIDE-A

Consorzio Oncotech

Phase 2 Unknown
75 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡